Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
Lok SW, De Boer R, Baron-Hay S, Button P, Devitt B, Forster BC, Fox P, Harold M, Ketheeswaran S, Kichenadasse G, Kiely BE, Marx G, Nott L, Pellegrini L, Tafreshi A, Gibbs P.
Lok SW, et al. Among authors: forster bc.
Int J Cancer. 2023 Jan 15;152(2):267-275. doi: 10.1002/ijc.34245. Epub 2022 Aug 25.
Int J Cancer. 2023.
PMID: 36005450